Adjuvant use of taxanes for patients with breast cancer: We see the tip of the Iceberg

Clinical Breast Cancer

Volumn 3, Issue 5, 2002, Pages 326-332

  Hudis, Clifford ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

5 flourouracil; Adjudant therapy; Concurrent therapy; Cyclophosphamide; Doxorubicin; Epirubicin; Methotrexate; Paclitaxel; Sequential therapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; ONCOPROTEIN; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA; LYMPH NODE; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING;

EID: 0036965586     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2002.n.035     Document Type: Review

References (13)

1. Heimann R, Hellman S. Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. J Clin Oncol 2000; 18:591-599.
2. Honig S. Hormonal Therapy and Chemotherapy. In: Harris J, Morrow M, Lippman ME, et al, eds. Disease of the Breast. Philadelphia, PA: Lippincott-Raven; 1996:669-734.
3. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists Collaborative Group. Lancet 1998; 352:930-942.
4. Bishop JF, Dewar J, Toner GC, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999; 17:2355-2364.
5. Nabholtz JM, North S, Smylie M, et al. Docetaxel (Taxotere) in combination with athracyclines in the treatment of breast cancer. Semin Oncol 2000; 27:11-18.
6. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus flourouracil, doxorubicin, and clyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001; 19:1707-1715.
7. Henderson I, Berry D, Demetri G, et al. Improved disease-free survival and overall survival from the addition of paclitaxel, but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc Am Soc Clin Oncol 1998; 17:101a (Abstract #390).
8. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 2001:5-15.
9. Mamounas E. Evaluating the use of paclitaxel following doxorubincin/cyclophosphamide in patients with breast cancer and positive axillary lymph nodes, NIH Consensus Development Conferences on Adjuvant Therapy, Silver Springs, MD, 2000.
10. Buzdar AU, Singletary SE, Valero V, et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 2002; 8:1073-1079.
11. Nabholtz JM, Pienkowski T, Mackey J, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 2002; 21:36a (Abstract #141).
12. NSABP. The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: preliminary results from NSABP Protocol B-27. Breast Cancer Res Treat 2001; 69:210 (Abstract #215).
13. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13: 2688-2699.